Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model

Lignende værker

• Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
  af: Chugh, R., et al.
  Udgivet: (2015)
• Cixutumumab
  af: McKian, Kevin P, et al.
  Udgivet: (2009)
• Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
  af: Qu, Xiao, et al.
  Udgivet: (2017)
• A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
  af: Wilky, B A, et al.
  Udgivet: (2015)
• Efficacy of anti-insulin like growth factor I receptor (IGF-IR) monoclonal antibody cixutumumab in mesothelioma is highly correlated with IGF-IR sites/cell
  af: Kalra, Neetu, et al.
  Udgivet: (2012)